Medivation News

Medivation, Inc. and Astellas Pharma Inc. Announce Initiation of Expanded Access Program for Enzalutamide in the United States SAN FRANCISCO, CA and TOKYO-- - Medivation, Inc.

Ariba's board of directors unanimously approved SAP's per share purchase price represents a 20% premium over the May 21 closing price.

SAN FRANCISCO, CA and TOKYO-- - Medivation, Inc. and Astellas Pharma Inc. announced that Medivation has submitted a New Drug Application to the U.S. Food and Drug Administration for enzalutamide .

HOTBEDS Regional News US & Canada Biotech Bay Biotech Beach Genetown Pharm Country BioCapital BioMidwest Bio NC BioForest Southern Pharm BioCanada East US Device Europe Asia Medivation, Inc.

Shares of Medivation traded up 2.11% during mid-day trading on Wednesday, hitting $87.94. Medivation has a 52 week low of $14.32 and a 52 week high of $88.51. The company's market cap is $3.188 billion.

Shares of Medivation traded up 2.11% during mid-day trading on Wednesday, hitting $87.94. Medivation has a 52 week low of $14.32 and a 52 week high of $88.51. The company's market cap is $3.188 billion.

David Hung, M.D., president and chief executive officer, will present at the Bank of America Merrill Lynch Health Care Conference on Wednesday, May 16 at 4:20p.m. Pacific Time in Las Vegas, NV.

The firm currently has an "outperform" rating on the stock. The analysts wrote, "MDVN announced Q1:12 EPS of $0.01, due to recognition of upfront and milestone payments from former partner Pfizer, and current partner Astellas.

BUYINS.NET / www.squeezetrigger.com is monitoring the performance of all stocks with earnings being released Tuesday, May 8th 2012 and determining how the stocks have performed After their last 12 quarterly, 6 quarterly and June earnings reports.